Details of the Drug

General Information of Drug (ID: DMQXU4C)

Drug Name
Anti-CD19-CAR vector-transduced T cells
Indication
Disease Entry ICD 11 Status REF
B-cell non-hodgkin lymphoma 2B33.5 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
Acute lymphoblastic leukaemia 2A85 Clinical trial [2]
B-cell chronic lymphocytic leukaemia 2A82.00 Clinical trial [2]
Diffuse large B-cell lymphoma 2A81 Clinical trial [2]
Follicular lymphoma 2A80 Clinical trial [2]
Haematopoietic/lymphoid cancer 2B33.5 Clinical trial [2]
Prolymphocytic leukaemia 2A82.1 Clinical trial [2]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D03UNT
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease B-cell non-hodgkin lymphoma
ICD Disease Classification 2B33.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma
2 ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19